Tiotropium Bromide Monohydrate/Fluticasone Propionate/Salmeterol xinafoate

噻托溴铵/丙酸氟替卡松/昔萘酸沙美特罗

Report date: 2025/11/14 13:58:47

Base Information

Drug NameTiotropium Bromide Monohydrate/Fluticasone Propionate/Salmeterol xinafoate
Drug Alias NameTiotropium Bromide Monohydrate-Fluticasone Propionate-Salmeterol xinafoate噻托溴铵+丙酸氟替卡松+昔萘酸沙美特罗Tiotropium Bromide Monohydrate+Fluticasone Propionate+Salmeterol xinafoate噻托溴铵-丙酸氟替卡松-昔萘酸沙美特罗Tiotropium Bromide Monohydrate/Salmeterol xinafoate/Fluticasone Propionate +[8] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionBeta-2 adrenergic receptor agonistsGlucocorticoid receptor agonistsMuscarinic acetylcholine receptor M3 antagonists +[4] 
TargetsBeta-2 adrenergic receptorGlucocorticoid receptorCytosolic phospholipase A2 +[4] 
Therapy Area/IndicationsPulmonary Disease, Chronic Obstructive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Tiotropium BromideFluticasone PropionateSalmeterol xinafoate
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHanmi Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic Obstructive

Other Information

ATC CodeN/A
Related LinksN/A